Status:
COMPLETED
Epidemiology and Pathophysiological Mechanisms of HTAP in SS and SC Children in Martinique and Guadeloupe.
Lead Sponsor:
Centre Hospitalier Universitaire de la Guadeloupe
Conditions:
Sickle Cell Disease
Eligibility:
All Genders
8-16 years
Phase:
NA
Brief Summary
pulmonary arterial hypertension (PAH) has been reported with a prevalence of approximately 30% in adult sickle cell disease (SCD) patients, with an increased mortality in SCD patients with PAH, compar...
Detailed Description
The primary aim of this study is to estimate the prevalence and the incidence of PAH in a population of SCD children (SS, SC) with similar medical caring, aged from 8 to 16 years old. Unlike the impo...
Eligibility Criteria
Inclusion
- children aged between 8 to 16 years old,
- SS homozygote or SC compound heterozygote, followed by the sickle cell centers of Guadeloupe and Martinique or by the pediatric department of the university hospital of Fort-de-France, identified by the systematic neonatal screening programs performed in Guadeloupe and Martinique or by other labeled centers, registered in the French medical social security national program, and for which the parental and the old children consent has been obtained.
Exclusion
- other hemoglobinopathies, chronic transfusion therapy programs or treatments which affected the expression of the biomarkers studied (unless hydroxyurea treatment),
- recent blood transfusion or phlebotomies (less than 3 months);
- patients not at steady state,
- pregnancy or breast feeding,
- refusal of parental and old children consent.
Key Trial Info
Start Date :
January 11 2010
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
October 17 2016
Estimated Enrollment :
185 Patients enrolled
Trial Details
Trial ID
NCT03368261
Start Date
January 11 2010
End Date
October 17 2016
Last Update
December 11 2017
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Hospital University Center of Martinique
Fort-de-France, Martinique, 97261